FDA Greenlights First Oral PCSK9 Inhibitor – Lipfendra

The U.S. Food and Drug Administration just gave the thumbs‑up to a brand‑new cholesterol medicine that you can take by mouth. Lipfendra – whose generic name is enlicitide – is the first oral drug in the PCSK9‑inhibitor family, a class that until now required weekly injections.

What makes Lipfendra special? It targets a protein called PCSK9, which normally tells the liver to let LDL‑cholesterol linger in the bloodstream. By blocking that protein, the pill helps the body pull the “bad” cholesterol out of the blood, leading to dramatic drops in LDL levels.

Two late‑stage trials showed the effect in plain numbers: patients with hypercholesterolemia who took the once‑daily tablet lowered their LDL by roughly 60 % on average. That’s a huge swing, especially for the roughly one‑quarter of adults who struggle with elevated LDL despite other treatments.

It’s not a replacement for statins, at least not right now. Merck, the drug’s maker, envisions Lipfendra as a complementary therapy – an add‑on for people already on statins but still missing their cholesterol targets. As Merck’s executive vice‑president Brian Foard put it, “Seventy percent of those patients treated with those therapies are still not achieving guideline‑recommended goals. We believe this is the opportunity.”

The new pill also shines for a trickier crowd: folks whose genes crank up cholesterol production. Lifestyle tweaks and diet can only do so much when a hereditary mutation is at play, and an oral PCSK9 blocker offers a practical way to tame those levels without the hassle of shots.

Another win for Lipfendra is safety. The injectable PCSK9 inhibitors on the market have occasionally sparked allergic reactions, but the trials for the oral version didn’t flag the same risk. Plus, the convenience factor can’t be ignored – many patients dislike injections, and primary‑care doctors often face paperwork hurdles to get patients on injectable therapy.

All told, the approval marks a notable shift in how we might manage cholesterol in the future. A pill that delivers the power of a biologic, without the needle, could open doors for millions who are currently undertreated for atherosclerotic cardiovascular disease.